Skip to main content

Table 4 Genotype frequencies of NOS polymorphisms among participants in the LHS cohort and their associations with lung function

From: Nitric oxide synthase polymorphisms, gene expression and lung function in chronic obstructive pulmonary disease

Gene SNP Genotype N Mean ± SE Baseline FEV1(% predicted) p-value*a p-value*b N Mean ± SE Rate of Decline in FEV1(% predicted) p-value*a p-value*b
NOS1 rs41279104 CC 2650 (79%) 78.39 ± 0.17 Referent 0.1424 2602 (79%) -0.97 ± 0.04 Referent 0.3530
CT 650(19%) 78.84 ± 0.37 0.7688 635 (19%) -1.02 ± 0.07 0.5332
TT 55 (2%) 79.33 ± 1.19 0.3825 52 (2%) -1.27 ± 0.26 0.3434
NOS2 rs8078340 GG 2760 (76%) 78.64 ± 0.17 Referent 0.1118 2705 (76%) -0.96 ± 0.03 Referent 0.1838
AG 794 (22%) 78.28 ± 0.32 0.7166 781 (22%) -1.03 ± 0.07 0.8221
AA 81 (2%) 77.82 ± 1.00 0.2977 81 (2%) -1.12 ± 0.20 0.4215
NOS3 rs1800779 AA 1448 (41%) 77.97 ± 0.24 Referent 0.0018 1425 (41%) -1.05 ± 0.05 Referent 0.3838
AG 1552 (44%) 78.81 ± 0.23 0.8034 1521 (44%) -0.92 ± 0.05 0.1149
GG 516 (15%) 79.31 ± 0.39 0.0273 504 (15%) -1.02 ± 0.07 0.7133
  1. *p-values were adjusted for age, sex, and smoking history (pack-years).
  2. ap-value for comparison to the wild type homozygous genotype.
  3. bp-value for the additive model.